肿瘤患者药物不良反应的频率:一项大学医院肿瘤科的研究。

IF 1 4区 医学 Q4 ONCOLOGY
Zeynep Erdogmus Ozgen, Barıs Asana, Muhammed Mansur Ozgen
{"title":"肿瘤患者药物不良反应的频率:一项大学医院肿瘤科的研究。","authors":"Zeynep Erdogmus Ozgen, Barıs Asana, Muhammed Mansur Ozgen","doi":"10.1177/10781552251358171","DOIUrl":null,"url":null,"abstract":"<p><p>ObjectivesWe aimed to investigate the adverse drug reactions (ADRs) observed in cancer patients, the drugs causing ADRs, ADRs reporting rate, common adverse effects, drug interactions, and the drugs used to manage these adverse effects.MethodsA questionnaire about pharmacovigilance, the most common ADRs and side effects observed in oncology patients, the frequency of these ADRs, the drugs causing them, and drug interactions was administered to the volunteers in our study.ResultsAlthough 66 out of the 90 nurses who participated in the study reported having previously encountered an ADR, only 39 of them actually reported it. ADRs were most frequently seen once a year or more and 56% of the ADRs were life-threatening, 21% medically important and 23% resulted in hospitalization. The pharmacological groups with the most ADR reports were; Taxanes, Platinum compounds, Monoclonal antibody (Mabs), Antimetabolites, Alkylating agents, Topoisomerase inhibitors and alkaloids respectively. ADRs were specifically related to Paclitaxel, Cisplatin and Rituximab. The most common adverse effects included; redness, itching, dyspnea and tachycardia. Antihistamines and corticosteroids were most commonly used in treatment of ADRs. The drugs that interacted most with antineoplastics were antibiotics, anticonvulsants and antihypertensives.ConclusionAlthough the incidence of ADRs in cancer patients is high, the reporting rate is relatively low. ADRs associated with antineoplastic drugs are serious reactions. Identifying which drugs cause the most ADRs is crucial for prevention, monitoring, and treatment.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251358171"},"PeriodicalIF":1.0000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Frequency of adverse drug reactions in cancer patients: A study at the oncology department of a university hospital.\",\"authors\":\"Zeynep Erdogmus Ozgen, Barıs Asana, Muhammed Mansur Ozgen\",\"doi\":\"10.1177/10781552251358171\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>ObjectivesWe aimed to investigate the adverse drug reactions (ADRs) observed in cancer patients, the drugs causing ADRs, ADRs reporting rate, common adverse effects, drug interactions, and the drugs used to manage these adverse effects.MethodsA questionnaire about pharmacovigilance, the most common ADRs and side effects observed in oncology patients, the frequency of these ADRs, the drugs causing them, and drug interactions was administered to the volunteers in our study.ResultsAlthough 66 out of the 90 nurses who participated in the study reported having previously encountered an ADR, only 39 of them actually reported it. ADRs were most frequently seen once a year or more and 56% of the ADRs were life-threatening, 21% medically important and 23% resulted in hospitalization. The pharmacological groups with the most ADR reports were; Taxanes, Platinum compounds, Monoclonal antibody (Mabs), Antimetabolites, Alkylating agents, Topoisomerase inhibitors and alkaloids respectively. ADRs were specifically related to Paclitaxel, Cisplatin and Rituximab. The most common adverse effects included; redness, itching, dyspnea and tachycardia. Antihistamines and corticosteroids were most commonly used in treatment of ADRs. The drugs that interacted most with antineoplastics were antibiotics, anticonvulsants and antihypertensives.ConclusionAlthough the incidence of ADRs in cancer patients is high, the reporting rate is relatively low. ADRs associated with antineoplastic drugs are serious reactions. Identifying which drugs cause the most ADRs is crucial for prevention, monitoring, and treatment.</p>\",\"PeriodicalId\":16637,\"journal\":{\"name\":\"Journal of Oncology Pharmacy Practice\",\"volume\":\" \",\"pages\":\"10781552251358171\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2025-07-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Oncology Pharmacy Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10781552251358171\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552251358171","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的探讨癌症患者的药物不良反应(adr)、引起adr的药物、adr报告率、常见不良反应、药物相互作用以及用于控制这些不良反应的药物。方法采用问卷调查的方法,对肿瘤患者的药物警戒性、最常见的不良反应及副反应、不良反应发生的频率、引起不良反应的药物及药物相互作用进行问卷调查。结果:虽然参与研究的90名护士中有66人报告曾遇到过不良反应,但其中只有39人真正报告了。不良反应最常见于一年一次或以上,56%的不良反应危及生命,21%具有医学意义,23%导致住院。不良反应报告最多的药理学组为;紫杉烷类、铂类化合物、单克隆抗体、抗代谢物、烷基化剂、拓扑异构酶抑制剂和生物碱。不良反应与紫杉醇、顺铂和利妥昔单抗相关。最常见的不良反应包括;红,痒,呼吸困难,心动过速。抗组胺药和皮质类固醇是治疗不良反应最常用的药物。与抗肿瘤药物相互作用最多的药物是抗生素、抗惊厥药和抗高血压药。结论肿瘤患者不良反应发生率虽高,但报告率相对较低。与抗肿瘤药物相关的不良反应是严重的反应。确定哪些药物引起最多的不良反应对预防、监测和治疗至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Frequency of adverse drug reactions in cancer patients: A study at the oncology department of a university hospital.

ObjectivesWe aimed to investigate the adverse drug reactions (ADRs) observed in cancer patients, the drugs causing ADRs, ADRs reporting rate, common adverse effects, drug interactions, and the drugs used to manage these adverse effects.MethodsA questionnaire about pharmacovigilance, the most common ADRs and side effects observed in oncology patients, the frequency of these ADRs, the drugs causing them, and drug interactions was administered to the volunteers in our study.ResultsAlthough 66 out of the 90 nurses who participated in the study reported having previously encountered an ADR, only 39 of them actually reported it. ADRs were most frequently seen once a year or more and 56% of the ADRs were life-threatening, 21% medically important and 23% resulted in hospitalization. The pharmacological groups with the most ADR reports were; Taxanes, Platinum compounds, Monoclonal antibody (Mabs), Antimetabolites, Alkylating agents, Topoisomerase inhibitors and alkaloids respectively. ADRs were specifically related to Paclitaxel, Cisplatin and Rituximab. The most common adverse effects included; redness, itching, dyspnea and tachycardia. Antihistamines and corticosteroids were most commonly used in treatment of ADRs. The drugs that interacted most with antineoplastics were antibiotics, anticonvulsants and antihypertensives.ConclusionAlthough the incidence of ADRs in cancer patients is high, the reporting rate is relatively low. ADRs associated with antineoplastic drugs are serious reactions. Identifying which drugs cause the most ADRs is crucial for prevention, monitoring, and treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.70
自引率
7.70%
发文量
276
期刊介绍: Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信